Skip to main content
. Author manuscript; available in PMC: 2012 Jan 17.
Published in final edited form as: JAMA. 2010 Nov 3;304(17):1903–1911. doi: 10.1001/jama.2010.1510

Figure 3.

Figure 3

Rate of Cognitive Change on Alzheimer’s Disease Assessment Scale (ADAS) Divided by Apolipoprotein E (APOE) Genotype

Error bars indicate 95% confidence intervals. The linear mixed-effects analysis finds no effect of docosahexaenoic acid (DHA) on the rate of ADAS-cog change in APOE ε4–positive participants but when the analysis is confined to APOE ε4-negative participants, the rate of change in ADAS-cog is slower in participants treated with DHA than in participants treated with placebo (linear mixed-effects model: P = .03). There was no evidence of a DHA effect on Clinical Dementia Rating sum of boxes, Alzheimer’s Disease Cooperative Study activities of daily living, or Neuropsychiatric Inventory on rates of brain atrophy (see “Results” section).